Implications of empirical administration of caspofungin in COVID-19 complicated fungal infections

Front Cell Infect Microbiol. 2023 Nov 21:13:1269543. doi: 10.3389/fcimb.2023.1269543. eCollection 2023.

Authors

Kazuhiro Itoh^{1

2}, Hiroshi Tsutani¹, Yasuhiko Mitsuke¹, Hiromichi Iwasaki²

Affiliations

¹ Department of Internal Medicine, NHO Awara National Hospital, Awara, Fukui, Japan.
² Division of Infection Control and Prevention, University of Fukui Hospital, Fukui, Japan.

No abstract available

Keywords: COVID-19; SARS-CoV-2; caspofungin; co-infection; fungal infections; spleen tyrosine kinase.

MeSH terms

Antifungal Agents / therapeutic use
COVID-19*
Caspofungin
Humans
Mycoses* / drug therapy

Substances

Caspofungin
Antifungal Agents

Grants and funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.